en es es es es es en pt es en es en en en es es fr en es es fr en en en en en en en en en en en en en en en en en en en es es en en en en en en es es es es es es es es pt pt pt en es es en es es es es es en es gl es es es es en es es es es en es es es es es es es es en es es es gu es
Leading National Cancer Groups Release Joint Statement to Chart the Future of Cancer Health Disparities Research - Renovatio Biomédica
Leading national cancer organizations have released a joint position statement to guide the future of cancer health disparities research. The statement represents a unified strategy by the American Association for Cancer Research (AACR), the American Cancer Society (ACS), the American Society of Clinical Oncology (ASCO), and the National Cancer Institute (NCI) to foster cooperation across the cancer research community to ensure that all patients – regardless of social demographics, socioeconomic status, or the communities in which they live – benefit from cancer research.
“The AACR is committed to eliminating cancer health disparities, and we hope that the recommendations put forward through this unprecedented collaboration will promote cooperation among all stakeholders in the cancer disparities research community to ensure that research-driven advances benefit all patients, regardless of their race, ethnicity, age, gender, socioeconomic status, and community in which they live,” said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR.
According to the statement, cancer health disparities are pronounced and well documented. Medically underserved populations, including racial and ethnic minorities and individuals of lower socioeconomic status, experience worse cancer outcomes. As the organizations discuss, disparities are driven by a range of multilevel patient, community, and structural factors, including sociodemographics, health care access, lifestyle factors, and biological and genetic differences. While understanding of underlying causes of cancer disparities is growing, emerging and increasing cancer disparities among some populations continue to create new challenges – requiring a deeper understanding of the multilevel, interrelated causes and how to effectively address them, according to the organizations.
The position statement was developed following a summit held by the groups, which brought together experts in clinical cancer research, epidemiology, public health, and health care policy, as well as patient advocates, to discuss the current state of cancer health disparities research and identify top priorities in the field.
​​​The joint statement, published simultaneously today by the four co-authoring organizations, outlines the following top research needs and priorities:
Defining and improving data measures and tools for cancer disparities research:Patient data are often incomplete, inaccurate, or overly-simplified and usually do not consider many social and community factors. Cancer disparities research is limited by a lack of comprehensive, consistent data on factors that impact disparities in cancer care and patient outcomes, including a patient’s social status and demographics, community and lifestyle factors, and biology and genetics, as well as by widespread variation in data collection methodology.
Addressing disparities in cancer incidence: Eliminating disparities in cancer incidence requires advancing knowledge of biological and environmental determinants of cancer incidence disparities, including a greater understanding of the role of genetics in contributing to higher cancer risk among certain populations.
Addressing cancer survival disparities: Currently, the interplay between system-level, biological, social, and environmental factors is often inadequately accounted for in cancer research. Counteracting growing disparities in cancer survival requires a more complete picture of the range of factors involved and how to track, identify, and address them.
Improving community engagement in cancer research: Poor translation of innovation in cancer care into health care systems in diverse communities has hampered the impact of innovative treatments and precision medicine advances on underserved patient populations. Ensuring that all patient populations benefit from advances in cancer care requires stronger community engagement in cancer research.
Redesigning cancer clinical trials to acknowledge and address cancer disparities: Recruitment and retention rates in cancer clinical trials are lower for some patient populations. Since clinical trials are the foremost means of generating reliable evidence on efficacy of treatments and patient care methods, changes to the clinical trials system are needed to improve the generalizability and applicability of clinical trial findings and better inform the care of underrepresented patient groups.​
The statement provides a series of recommendations to address each of these outlined needs, with a particular focus on guiding investments in cancer health disparities research. In addition to specific recommendations in each of these areas, the statement also includes broad action items that can be taken to further the field of cancer research disparities as a whole, based on the current landscape and existing priorities.
Investigators, research sponsors, and research publications should insist on the use of the highest-quality data measurement tools and the most granular data for conducting cancer disparities research.
Establishment of a health disparities research network and multiple consortia to gather relevant patient contextual data and biospecimens are needed to effectively inform cancer disparities research that examines the multilevel factors involved in causing cancer disparities.
Best practice strategies should be designed and utilized to engage underserved populations in research studies and ensure they are informed of clinical trial opportunities.
Researchers should be adequately trained in community engagement research tactics, and academic promotions should appropriately account for time needed to conduct community engagement research. Expectations for the possible need for funding beyond funding cycles should be made for community engagement research.
Cancer treatment systems should ensure real-time monitoring of patient experiences to understand how patients are being treated and intervene when care and outcomes disparities are identified.
“Charting the Future of Cancer Health Disparities Research: A Position Statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute,” was published July 24 in Cancer Research.​
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors
Data resources for the identification and interpretation of actionable mutations by clinicians
Mike Stratton will lead an international team to help transform our understanding of what causes cancer
Mutaciones en el ADN no codificante protegen al cerebro de la ELA mayo 24, 2022
La amplificación de MET predice el beneficio de la terapia dirigida con crizotinib en NSCLC marzo 16, 2022
Inmunoterapia para el cáncer de cabeza y cuello: un cambio de paradigma de la quimioterapia de inducción a la inmunoterapia neoadyuvante febrero 14, 2022
Estudio prospectivo unicéntrico sobre la eficacia de nivolumab contra el carcinoma de células escamosas de cabeza y cuello recurrente o metastásico, sensible al platino febrero 13, 2022
Los científicos de los NIH construyen un modelo celular de las lesiones de la esclerosis múltiple septiembre 11, 2021
Archivos Elegir el mes mayo 2022 marzo 2022 febrero 2022 septiembre 2021 mayo 2021 abril 2021 marzo 2021 febrero 2021 enero 2021 diciembre 2020 noviembre 2020 septiembre 2020 agosto 2020 julio 2020 junio 2020 mayo 2020 febrero 2020 enero 2020 diciembre 2019 octubre 2019 julio 2019 junio 2019 mayo 2019 abril 2019 marzo 2019 febrero 2019 enero 2019 diciembre 2018 noviembre 2018 octubre 2018 septiembre 2018 junio 2018 abril 2018 febrero 2018 enero 2018 diciembre 2017 agosto 2017 julio 2017 junio 2017 mayo 2017 abril 2017 marzo 2017 febrero 2017
Renovatio es una consultora especializada en el diseño, gestión y desarrollo de proyectos multidisciplinares, formación y comunicación en biomedicina.
Mutaciones en el ADN no codificante protegen al cerebro de la ELA mayo 24, 2022
La amplificación de MET predice el beneficio de la terapia dirigida con crizotinib en NSCLC marzo 16, 2022
Inmunoterapia para el cáncer de cabeza y cuello: un cambio de paradigma de la quimioterapia de inducción a la inmunoterapia neoadyuvante febrero 14, 2022
Inmunoterapia para el cáncer de cabeza y cuello: un cambio de paradigma de la quimioterapia de inducción a la inmunoterapia neoadyuvante
Estudio prospectivo unicéntrico sobre la eficacia de nivolumab contra el carcinoma de células escamosas de cabeza y cuello recurrente o metastásico, sensible al platino
© 2022 Renovatio Biomédica. All rights reserved
Gestionar el consentimiento de las cookies
Para ofrecer las mejores experiencias, utilizamos tecnologías como las cookies para almacenar y/o acceder a la información del dispositivo. El consentimiento de estas tecnologías nos permitirá procesar datos como el comportamiento de navegación o las identificaciones únicas en este sitio. No consentir o retirar el consentimiento, puede afectar negativamente a ciertas características y funciones.
Funcional Funcional Siempre activo
El almacenamiento o acceso técnico es estrictamente necesario para el propósito legítimo de permitir el uso de un servicio específico explícitamente solicitado por el abonado o usuario, o con el único propósito de llevar a cabo la transmisión de una comunicación a través de una red de comunicaciones electrónicas.
El almacenamiento o acceso técnico es necesario para la finalidad legítima de almacenar preferencias no solicitadas por el abonado o usuario.
El almacenamiento o acceso técnico que es utilizado exclusivamente con fines estadísticos. El almacenamiento o acceso técnico que se utiliza exclusivamente con fines estadísticos anónimos. Sin un requerimiento, el cumplimiento voluntario por parte de tu Proveedor de servicios de Internet, o los registros adicionales de un tercero, la información almacenada o recuperada solo para este propósito no se puede utilizar para identificarte.
El almacenamiento o acceso técnico es necesario para crear perfiles de usuario para enviar publicidad, o para rastrear al usuario en una web o en varias web con fines de marketing similares.